As the 12th generic company in the world, Pliva has the option of either making smaller acquisitions or merging with partners, Covic said, adding that the offer of the Icelandic company Actavis was one of the options.
Commenting on Actavis's non-binding offer of 570 kuna per share, Covic said that the company and he were under strong pressure. The financial advisor Deutsche Bank has been hired to consider all options to see what should be done next, Covic said.
Regardless of what the final decision may be, the process will be transparent, Covic said, describing Actavis's offer as unfair and unfriendly.